Pecyk R A, Fraser-Smith E B, Matthews T R
Syntex Research, Palo Alto, California 94304.
Infect Immun. 1989 Oct;57(10):3257-8. doi: 10.1128/iai.57.10.3257-3258.1989.
Prophylactic treatments with either recombinant human interleukin-1 beta (rHuIL-1 beta) or a muramyl dipeptide analog ([Abu1]MDP) enhanced the resistance of mice to systemic infection with Candida albicans. The optimum treatment regimen in both normal and cyclophosphamide-treated mice was intraperitoneal administration of 100 ng of rHuIL-1 beta or 1.6 mg of [Abu1]MDP per mouse once daily for 3 consecutive days before infection. Neither rHuIL-1 beta nor [Abu1]MDP was efficacious when started after the infection or when given before cyclophosphamide to mice infected subsequently. Continuing to treat after the infection with either drug neither enhanced nor antagonized the efficacy of prophylactic treatments.
用重组人白细胞介素-1β（rHuIL-1β）或一种胞壁酰二肽类似物（[Abu1]MDP）进行预防性治疗可增强小鼠对白色念珠菌全身感染的抵抗力。在正常小鼠和环磷酰胺处理的小鼠中，最佳治疗方案均为在感染前连续3天每天腹腔注射每只小鼠100 ng的rHuIL-1β或1.6 mg的[Abu1]MDP。在感染后开始治疗或在环磷酰胺给药前给予随后感染的小鼠时，rHuIL-1β和[Abu1]MDP均无效。感染后继续用这两种药物中的任何一种进行治疗既不会增强也不会拮抗预防性治疗的效果。
